Evaluation of the Association with Cervical Cancer of Polymorphisms in Syndecan-1, a Heparan Sulfate Proteoglycan Involved with Viral Cell Entry
- Kelly J. Yu1,
- Arman Bashirova2,
- Margaret M. Madeleine3,4,
- Jie Cheng2,
- Lisa G. Johnson3,
- Stephen M. Schwartz3,4,
- Mary Carrington5 and
- Allan Hildesheim1
- 1Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland; 2Johns Hopkins University School of Medicine, Baltimore, Maryland; 3Division of Public Health Sciences, Fred Hutchinson Cancer Research Center; 4Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, Washington; and 5Laboratory of Genomic Diversity, Science Applications International Corporation-Frederick, Inc., NCI-Frederick, Frederick, Maryland
- Requests for reprints:
Kelly J. Yu, Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute, 6120 Executive Boulevard, Suite 550, Bethesda, MD 20852. Phone: 301-496-1691; Fax: 301-402-0916. E-mail: yuke{at}mail.nih.gov
Abstract
Infection with 1 of ∼15 oncogenic human papillomaviruses is known to be linked to the development of all histologic forms of cervical cancer. We evaluated whether polymorphisms in syndecan-1 (SDC-1), a gene whose protein product is believed to be involved in human papillomavirus entry into epithelial cells, were associated with histologic subtypes of cervical cancer. A total of 293 in situ/invasive adenocarcinoma cases, 260 in situ/invasive squamous cell carcinoma cases, and 478 controls from two studies conducted in the Eastern United States and Seattle area were evaluated. DNA from peripheral blood was used for testing. We sequenced 5 exons and 60 nucleotides upstream of the start codon for SDC-1 in a random subset of 50 cases and 50 controls from the Eastern U.S. Study and identified two polymorphisms (E84E, rs2230924 and Pro-27 C → T, rs11544860). PCR-based testing was done to evaluate risk associated with these two polymorphisms. Polymorphisms of SDC-1 were not associated with risk of squamous cell carcinomas of the cervix. Similarly, there was no evidence for an association between SDC-1 exon 3 polymorphisms and risk of cervical adenocarcinomas. A marginally significant increase in risk of cervical adenocarcinoma was associated with the presence of the Pro-27 polymorphism (pooled odds ratios, 1.6; 95% confidence intervals, 0.99-2.6), an effect that was restricted to the Eastern U.S. Study. Our results indicate a lack of association between SDC-1 polymorphisms and risk of squamous cell carcinomas of the cervix. An association between SDC-1 Pro-27 polymorphism and cervical adenocarcinoma cannot be ruled out. (Cancer Epidemiol Biomarkers Prev 2007;16(11):2504–8)
Footnotes
-
Grant support: This project was funded in whole or in part with federal funds from the National Cancer Institute, NIH, under contract N01-CO-12400 and grants P01CA042792, R01CA112512, and DA 13324. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.
-
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
Note: The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
-
- Accepted August 21, 2007.
- Received March 22, 2007.
- Revision received August 13, 2007.
